Aducanumab for Alzheimer’s disease?

As current treatments have only marginal benefit at best, editorial discusses implication of aducanumab’s controversial approval in US and concludes approval on a technicality could undermine regulatory standards designed to protect against false hope & set a dangerous precedent.

Source:

British Medical Journal